NCT06746766 Registry Study on Rare Cancers in Korea
| NCT ID | NCT06746766 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yonsei University |
| Condition | Rare Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2024-11-18 |
| Primary Completion | 2027-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2024-11-18 with a primary completion date of 2027-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to determine the participation rate of patients with registered rare cancers in clinical research.
Eligibility Criteria
Inclusion Criteria: * Adults aged ≥19 years * Confirmed rare cancer * Life expectancy ≥3 months Exclusion Criteria: -Serious or unstable medical/psychiatric conditions
Contact & Investigator
Hyo Song Kim, MD, Ph.D
PRINCIPAL INVESTIGATOR
Yonsei Cencer center
Frequently Asked Questions
Who can join the NCT06746766 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Rare Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06746766 currently recruiting?
Yes, NCT06746766 is actively recruiting participants. Contact the research team at hyosong77@yuhs.ac for enrollment information.
Where is the NCT06746766 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT06746766 clinical trial?
NCT06746766 is sponsored by Yonsei University. The principal investigator is Hyo Song Kim, MD, Ph.D at Yonsei Cencer center. The trial plans to enroll 500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.